Esperions Q3 Loss Wider Than Expected, Revenues Rise YY
ESPR Stock | USD 2.54 0.03 1.17% |
Slightly above 55% of Esperion Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Esperion Therapeutics suggests that many traders are impartial. Esperion Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Esperion Therapeutics. Many technical investors use Esperion Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Esperion |
ESPR reports a wider-than-expected loss for the third quarter of 2024. Revenues also lag estimates. Stock down in pre-market trading.
Read at finance.yahoo.com
Esperion Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Esperion Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Esperion Therapeutics Fundamental Analysis
We analyze Esperion Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Esperion Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Esperion Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Market Capitalization
Market Capitalization Comparative Analysis
Esperion Therapeutics is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Esperion Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Esperion Therapeutics stock to make a market-neutral strategy. Peer analysis of Esperion Therapeutics could also be used in its relative valuation, which is a method of valuing Esperion Therapeutics by comparing valuation metrics with similar companies.
Peers
Esperion Therapeutics Related Equities
SIGA | SIGA Technologies | 4.69 | ||||
IRWD | Ironwood Pharmaceuticals | 4.26 | ||||
ANIP | ANI Pharmaceuticals | 2.64 | ||||
PBH | Prestige Brand | 1.19 | ||||
LFCR | Lifecore Biomedical | 0.81 | ||||
ALKS | Alkermes Plc | 0.24 | ||||
ITCI | Intracellular | 0.19 | ||||
AVDL | Avadel Pharmaceuticals | 0.18 | ||||
KMDA | Kamada | 0.17 | ||||
PCRX | Pacira BioSciences, | 0.83 | ||||
CTLT | Catalent | 0.88 | ||||
NBIX | Neurocrine Biosciences | 1.03 | ||||
RMTI | Rockwell Medical | 1.33 | ||||
COLL | Collegium Pharmaceutical | 1.54 | ||||
PAHC | Phibro Animal | 1.70 | ||||
ELAN | Elanco Animal | 1.94 |
Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.